Triaging suspected cancer with a multi-cancer early detection blood test
- PMID: 37352874
- DOI: 10.1016/S1470-2045(23)00288-7
Triaging suspected cancer with a multi-cancer early detection blood test
Conflict of interest statement
I report receiving consulting fees or honoraria from Haystack Oncology, Seres Therapeutics, Amgen, Servier, Beigene, Novartis, Astra Zeneca, Merck Serono, MSD, Pierre Fabre, BMS, Daichii Sankyo, Illumina, Takeda, and Gilead.
Comment on
-
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.Lancet Oncol. 2023 Jul;24(7):733-743. doi: 10.1016/S1470-2045(23)00277-2. Epub 2023 Jun 20. Lancet Oncol. 2023. PMID: 37352875
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical